TLSA is a biotechnology company focused on the discovery and development of novel molecules to treat high unmet medical needs in immunology and oncology. Their lead product candidate in immunology is Foralumab (TZLS-401), which is the only fully human anti-CD3 monoclonal antibody (mAb), in clinical development. MAbs represent a single pure antibody produced by single clones and are an important class of human therapeutics for treating cancers and autoimmune diseases. Generation of antibodies for use in humans developed in animals can lead to strong immune responses limiting their effectiveness and potentially leading to severe side effects. Humanization removes most of the animal components of the antibody and lowers the immune response from the human immune system. Their lead product candidate in oncology is Milciclib (TZLS-201), which is an orally bioavailable, small molecule broad spectrum inhibitor of cyclin-dependent kinases (CDKs), and Src family kinases. CDKs are a highly conserved family of enzymes that phosphorylate a specific group of proteins that are involved in regulating the cell cycle. They also have a drug discovery pipeline of small molecule new chemical entities (NCEs), and biologics.